Multiple myeloma – mycolab.ai

Exploring the Therapeutic Potential of Ganoderma lucidum in Cancer

mycolabadmin

Ganoderma lucidum, a mushroom used in traditional medicine for thousands of years, shows promise in fighting certain blood cancers like leukemia and lymphoma. The mushroom contains special compounds that can kill cancer cells in multiple ways—by triggering cancer cell death, boosting the immune system, and preventing cancer cell growth. While laboratory studies are very encouraging, more testing in humans is needed before it can be used as a standard cancer treatment.

The Potential of Mushroom Extracts to Improve Chemotherapy Efficacy in Cancer Cells: A Systematic Review

mycolabadmin

This systematic review examines how mushroom extracts can make chemotherapy more effective at treating cancer, particularly by helping overcome cancer cells’ resistance to drugs. Researchers found that various mushroom species contain compounds that work together with chemotherapy drugs to kill cancer cells more effectively through different cellular mechanisms. The results suggest mushroom extracts could be a promising natural complement to conventional cancer treatments, though more research is needed before they can be used clinically.

Current Uses of Mushrooms in Cancer Treatment and Their Anticancer Mechanisms

mycolabadmin

This comprehensive review examines how medicinal mushrooms can help treat cancer. Certain mushroom species and their compounds, particularly polysaccharides, can boost the immune system to fight cancer cells, reduce chemotherapy side effects, and overcome drug resistance. Multiple mushrooms are currently in clinical trials showing promise in improving cancer patient outcomes when used alongside conventional treatments.

Breakthrough Invasive Mould Infections Under Posaconazole Prophylaxis in Patients With Haematologic Malignancies: A Case–Control Study

mycolabadmin

This study examined cases where patients receiving posaconazole to prevent fungal infections still developed serious mould infections despite the medication. Researchers compared 29 patients who developed these breakthrough infections with 46 control patients who did not. They found that over half of patients with breakthrough infections died, compared to only 20% of controls, and that surgical treatment significantly improved survival for certain types of fungal infections.

Invasive Fungal Disease is Rare in Multiple Myeloma Patients Treated with BCMA CAR-T Therapy

mycolabadmin

Researchers studied 234 multiple myeloma patients who received a cutting-edge cancer treatment called BCMA CAR-T therapy. While this therapy can cause serious side effects related to immune system activation, the study found that dangerous fungal infections were surprisingly rare, occurring in only 1.7% of patients. However, when fungal infections did occur in these patients, they tended to be severe and life-threatening, highlighting the need for careful monitoring of high-risk patients.

Recent Discoveries on Marine Organism Immunomodulatory Activities

mycolabadmin

Scientists are discovering that creatures from the ocean produce powerful substances that can help our immune system fight diseases like cancer and inflammation. These marine organisms—from tiny algae to sponges to fish—create natural compounds that can either boost or calm down our immune response depending on what we need. Several of these ocean-derived medicines are already approved for treating serious diseases, and many more are being tested in clinical trials. The ocean covers 70% of our planet and most of it remains unexplored, suggesting there are many more beneficial compounds waiting to be discovered.

Invasive Fungal Disease is Rare in Multiple Myeloma Patients Treated with BCMA CAR-T Therapy

mycolabadmin

Researchers studied patients with multiple myeloma who received a new type of cancer treatment called BCMA CAR-T cell therapy. While this powerful therapy can sometimes increase infection risk, the study found that serious fungal infections occurred in only a small percentage of patients (1.7%). However, when these fungal infections did occur, they were often severe and potentially life-threatening, particularly in patients who experienced significant side effects from the therapy.

Incidence And Risk Factors for Invasive Fungal Infections in Pre-Transplant and Transplant-Ineligible Multiple Myeloma in the U.S.: A Claims Analysis (2017-2021)

mycolabadmin

This study examined fungal infections in patients with multiple myeloma who were not eligible for or preparing for stem cell transplants. Researchers found that 6% of these patients developed invasive fungal infections, with yeast infections being the most common type. The risk of these infections was significantly higher in patients taking dexamethasone (a steroid) or those with low white blood cell counts and those receiving multiple cancer therapies.

Disease: Multiple myeloma